<DOC>
	<DOCNO>NCT01104662</DOCNO>
	<brief_summary>This multicenter , randomize , evaluator-blinded , comparator-controlled study . Participants randomize ( 1:1 ) daptomycin comparator , stratify degree renal impairment ( creatinine clearance [ CLcr ] 30 - 50 milliliter per minute [ mL/min ] [ moderate impairment ] &lt; 30 mL/min [ severe impairment ] ) type infection ( bacteremia complicate skin skin structure infection [ cSSSI ] ) create 4 cohort define follow : - Cohort 1 : Bacteremia CLcr &lt; 30 mL/min - Cohort 2 : Bacteremia CLcr 30 - 50 mL/min - Cohort 3 : cSSSI CLcr &lt; 30 mL/min - Cohort 4 : cSSSI CLcr 30 - 50 mL/min Participants treat evaluated safety microbiological clinical efficacy accordance type infection degree renal impairment . Peak trough sample collect assess exposure daptomycin participant Day 1 follow 5th dose .</brief_summary>
	<brief_title>Study Daptomycin Safety Efficacy Complicated Skin Skin Structure Infections ( cSSSI ) Bacteremia Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Oxacillin</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Nafcillin</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<criteria>Written inform consent Male female ≥18 year age Diagnosis cSSSI Staphylococcus aureus ( S. aureus ) bacteremia Renal impairment CLcr 30 50 mL/min CLcr &lt; 30 mL/min per CockcroftGault equation use actual body weight Functioning hemodialysis access stable regimen receive dialysis In appropriate health study acute chronic illness could adversely impact safety ability complete study Specific inclusion criterion cSSSI : Presence wound infection , major abscess , severe carbunculosis , infected ulcer , dialysis access site infection , type infection presence complicate factor At least 3 follow symptom , sign , laboratory value skin infection : elevated temperature ; elevate white blood cell ( WBC ) count ; pain ; tenderness ; swell ; erythema great 1 centimeter ( cm ) beyond wound edge ; induration ; pu formation Evidence Grampositive infect pathogen indicate positive Gram stain culture obtain within 96 hour prior study drug administration Infection sufficient severity require parenteral antimicrobial therapy Specific inclusion criterion S. aureus bacteremia : • Documented S. aureus bacteremia define least one positive blood culture S. aureus obtain within 96 hour prior first dose study medication Pregnant lactating female , unwilling practice barrier method birth control Received investigational drug ( include experimental biologic agent ) within 30 day study entry Unable discontinue use HMGCoA reductase inhibitor therapy study Known allergy intolerance daptomycin , penicillin , vancomycin Active intravenous ( IV ) drug abuse Confirmed suspect osteomyelitis , septic arthritis , meningitis , epidural abscess , intraabdominal infection , pneumonia , infective endocarditis Required use nonstudy systemic antibacterial agent activity target pathogen History muscular disease Neurological disease except stroke &gt; 6 month prior study entry Intramuscular injection within 7 day study drug administration Moribund clinical condition ( high likelihood death next 3 day ) Shock hypotension ( supine systolic blood pressure &lt; 80 millimeter mercury [ mmHg ] ) Body mass index ( BMI ) &lt; 18 &gt; 40 kilogram per meter square ( kg/m^2 ) [ BMI = weight ( kg ) /height ( m^2 ) ] Known human immunodeficiency virus ( HIV ) infection CD4 count ≤200 cells/millimeter ( mm ) ^3 Neutropenic participant absolute neutrophil count ≤500 cells/mm^3 Anticipated develop neutropenia absolute neutrophil count ≤500 due prior plan chemotherapy Alanine aminotransferase ( ALT ) value &gt; 3 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) value &gt; 3 × ULN Total bilirubin value ≥ 1.5 x ULN associate ALT value &gt; 3 x ULN Creatine phosphokinase ( CPK ) value &gt; 2 × ULN Hemoglobin &lt; 8 gram per deciliter ( gm/dL ) Unlikely comply study procedure return evaluation History rhabdomyolysis Prior enrollment study Infections cause Grampositive pathogen know resistant daptomycin select comparator agent Specific exclusion criterion cSSSI : Minor superficial skin infection primary site infection Cellulitis erysipelas associate complicate factor primary site infection Perirectal abscess , hidradenitis suppurativa , concomitant gangrene , myositis , multiple infected ulcer distant site , necrotizing fasciitis , infect thirddegree burn wound Infections require emergency surgery Infections suspect document due exclusively gramnegative , anaerobic , fungal organism Confirmed suspect disorder could interfere evaluation ( example , primary skin disorder ) Use topical antibiotic site infection Use systemic antibacterial therapy infection &gt; 24 hour within 48 hour prior start study drug unless ( ) infect Grampositive pathogen resistant therapy ( b ) therapy administer 3 day worsen improvement Planned surgical treatment consider curative infection Specific exclusion criterion S. aureus bacteremia : Has intravascular foreign material time positive blood culture drawn ( example. , intracardiac pacemaker wire , percutaneous implant venous catheter , vascular graft ) unless material remove within 4 day first dose study medication approval medical monitor ( exception : vascular stent place &gt; 6 month , permanent pacemaker attach via epicardial lead , dialysis access device unless material felt infect ) Prosthetic heart valve Cardiac decompensation valve damage high likelihood valve surgery 3 day randomization Polymicrobial blood infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>